Atai Life Sciences and Recognify Life Sciences reported on the same clinical trial results on July 28, 2025.
3 reports, 2 independent
Updated Jul 28
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Atai Life Sciences and Recognify Life Sciences reported on the same clinical trial results on July 28, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Two companies shared clinical trial results on July 28, 2025.1 source
Atai pivots to psychedelic programs after Recognify trial failure.1 source
- Study included patients in the US and UK starting July 1, 2025.
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaRecognify’s Phase IIb trial of schizophrenia therapy fails to meet primary goal atai Life Sciences (ATAI) company Recognify Life Sciences has reported that its Phase IIb trial of oral compound, inida
- GuruFocus.comATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News July 28 - Atai Life Sciences (NASDAQ:ATAI) shares slid 9% in pre?market trading on Monday after Recognify Life Sciences, an Atai?backed co
- Unknown outlet